Adcock Ingram Critical Care (Pty) Ltd and Scientific Group (Pty) Ltd / Scientific Group Investments (Pty) Ltd (70/LM/Aug05) [2005] ZACT 77 (3 November 2005)

Adcock Ingram Critical Care (Pty) Ltd and Scientific Group (Pty) Ltd / Scientific Group Investments (Pty) Ltd (70/LM/Aug05) [2005] ZACT 77 (3 November 2005)

The Tribunal found that the merger would not substantially prevent or lessen competition in any relevant market. The pathology market, where the parties' activities overlapped, would remain competitive post-merger, with the merged entity holding less than 15% market share and facing strong multinational rivals. In the hospital product market, the parties did not compete directly due to non-substitutable products. The Tribunal also accepted the parties' assurance that no jobs would be lost, thus no adverse public interest concerns arose. Accordingly, the merger was approved without conditions.

Citation
[2005] ZACT 77
Parties
Applicant: Adcock Ingram Critical Care (Pty) Ltd; Respondent: Scientific Group (Pty) Ltd; Respondent: Scientific Group Investments (Pty) Ltd
Court
Competition Tribunal
Jurisdiction
South Africa
Judgment Date
3 November 2005
Case Number
70/LM/Aug05
Procedural Posture
Large Merger / Merger Approval
Outcome
Merger approved without conditions.
Judges
D Lewis, N Manoim, Y Carrim
Legal Topics
Merger Control, Market Definition, Public Interest, Market Share Analysis
Competition Law Commercial and Corporate Merger Control Market Definition Public Interest Market Share Analysis

Case Brief

Summary, issues, holding and outcome

More case intelligence is available

Unlock the full research layer for this judgment.

Full judgment text Downloadable case file Legal principles 2 Authorities cited 1 Party arguments 2 Amounts and remedies 5
Sign in to unlock

Parties

Adcock Ingram Critical Care (Pty) Ltd

Applicant

Scientific Group (Pty) Ltd

Respondent

Scientific Group Investments (Pty) Ltd

Respondent

Procedural Posture

Large Merger / Merger Approval

Legal Issues

  1. 1 Whether the proposed merger would substantially prevent or lessen competition in the pathology and hospital product markets.
  2. 2 Whether the transaction raises any significant public interest concerns, including potential job losses.

Ratio Decidendi

The Tribunal found that the merger would not substantially prevent or lessen competition in any relevant market. The pathology market, where the parties' activities overlapped, would remain competitive post-merger, with the merged entity holding less than 15% market share and facing strong multinational rivals. In the hospital product market, the parties did not compete directly due to non-substitutable products. The Tribunal also accepted the parties' assurance that no jobs would be lost, thus no adverse public interest concerns arose. Accordingly, the merger was approved without conditions.

Court Disposition

Merger approved without conditions.

Orders

  • The merger between Adcock Ingram Critical Care (Pty) Ltd and Scientific Group (Pty) Ltd & Scientific Group Investments (Pty) Ltd is approved without conditions.